Our RIPTAC therapeutics hold two proteins together: one that is tumor-specific and another that performs an essential function. The novel protein-protein interaction results in selective killing of the cancer cell.
February 14, 2023
Halda Therapeutics unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO GU Symposium
February 14, 2023
The Halda origin story: Taking hold on cancer with a new drug modality